Navigation Links
First Coronary Stent on Drug Eluting Balloon Implanted

HELMOND, The Netherlands, May 25, 2010 /PRNewswire/ -- Blue Medical today announced a major step forward in its quest to improve the quality of life of patients with cardiovascular disease, with the start of the PIONEER trial, in which a new safe concept of stent-drug combination is evaluated.

PIONEER, as part of Blue Medical's clinical program, is the trial that enables for the first time the delivery of a coronary stent that is mounted on a Drug Eluting Balloon. On placement of the stent a predetermined load of Paclitaxel is delivered to the vessel wall to support the vessel in adapting to the stent and reducing adverse effects in the first days after implantation.

The team of investigator Dr. Jacques Koolen enrolled the first patient in the Catharina Hospital Eindhoven. This will soon be followed by enrollment in five additional centers in the Netherlands under guidance of the Principal Investigator, Dr. Peter Smits of Maasstad Hospital Rotterdam.

The Drug Eluting Balloon product in the PIONEER trial delivers drugs at the stent placement only, instead of continous drug delivery by drug eluting stents. This reduces the period that medication is needed, which means total procedure costs are reduced significantly. The new procedure improves a patient's comfort, as the period for which he has to take daily antiplatelet medication is reduced from up to two years to one month.

A coronary balloon angioplasty is a minimally invasive procedure performed to improve blood flow to the heart muscle. In an angioplasty procedure a balloon is inflated to open the coronary artery. In addition, a small wire mesh tube, called a stent, may be permanently placed to help the artery to remain open. Drug eluting stents, which release drug from the stent surface after implantation, are commonly used to prevent re-closure of the vessel. A downside is that patients are required to take antiplatelet medication daily for a long period with significant discomfort and risks associated.


About Blue Medical

Located in the Dutch Brainport area, Blue Medical ( is a global medical devices company and innovator in the treatment of cardiovascular diseases. The company develops, manufactures and markets innovative medical products for cardiovascular diseases. Every year over 50,000 patients worldwide are treated with devices of Blue Medical.

SOURCE Blue Medical
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ExpertRECALL Awards First Scholarships for Product-Safety Education
2. China Yongxin Pharmaceuticals Reports First Quarter 2010 Financial Results
3. Physicians Cite Positive First Clinical Experience with Volcanos Eagle Eye® Platinum Digital IVUS Catheter
4. In a World First, Asda Announces Not for Profit Price on All Cancer Treatment Drugs
5. Concord Medical to Report First Quarter 2010 Financial Results on Thursday, May 27, 2010
6. Heska Announces First Installation of New Blood Gas & Electrolyte Analyzer
7. WellPoint Is First Health Benefits Company to Release CER Guidelines for Use in Evaluating Pharmaceuticals
8. China Ruitai International Holdings Co., Ltd. Reports Results for the First Quarter 2010
9. Medical Product Outsourcing Magazine Announces the First Annual CardioTec Conference
10. China Sky One Medical Announces First Quarter 2010 Results
11. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results
Post Your Comments:
(Date:10/12/2015)... New York , October 12, 2015 ... (FMI) delivers key insights on the global vital signs monitoring ... Devices Market: Global Industry Analysis and Opportunity Assessment 2015-2025." The ... at a healthy CAGR of 9.5% and 9.2% in terms ... to factors, regarding which FMI offers major insights in detail ...
(Date:10/12/2015)... Oct. 12, 2015 Beginning October 1, 2015 ... Partner, the fastest growing practice management system for therapists, ... easily converts all patient diagnostic codes from the former ... --> --> Therapy Partner has ... mental health practitioners to easily understand the conversion to ...
(Date:10/12/2015)... , Oct. 12, 2015 Indivior PLC (LON: INDV) ... of Delaware granted the Company,s motion ... Abbreviated New Drug Application (ANDA) No. 205299 to market a ... and naloxone) Sublingual Film (CIII) in the United ... Since August 2013, Indivior has received Paragraph IV certifications ...
Breaking Medicine Technology:
(Date:10/12/2015)... ... October 12, 2015 , ... To help ... its charitable donation to the National Breast Cancer Foundation. The National Breast Cancer ... breast cancer through early detection, education, and support services. , The annual campaign ...
(Date:10/12/2015)... ... October 12, 2015 , ... SQM Group ... a contact channel benchmarking study. Be a part of this insightful ... for improving customer experience, customer journey, contact channel execution and intelligence, workforce optimization, ...
(Date:10/12/2015)... ... ... Holcomb – Kreithen Plastic Surgery and MedSpa, PLLC (“Holcomb – Kreithen”), one of ... Surgery University,” an educational series of mini seminars covering aesthetic and plastic surgery options, ... Saturday, October 24, 2015. , The goal of the event is to provide hands-on ...
(Date:10/12/2015)... ... October 12, 2015 , ... The Asthma and ... Engagement Award by the Patient-Centered Outcomes Research Institute (PCORI) for a new project ... , The project, entitled “Training Patients with Asthma to Understand and Participate in ...
(Date:10/12/2015)... ... October 12, 2015 , ... International law firm Greenberg ... with the U.S. Biomedical Advanced Research and Development Authority (BARDA) reported to be ... ReCell® Autologous Cell Harvesting Device under a U.S. mass casualty preparedness program. ...
Breaking Medicine News(10 mins):